| Revenue | Number of Estimates | | | | 7 | 7 | 12 | 12 |
| Revenue | Highest | | | | 5,875.2 | 11,619.2 | 23,769.1 | 25,099.4 |
| Revenue | Consensus (Mean) | 5,571.0 | 11,202.0 | 22,554.0 | 5,822.4 | 11,566.4 | 23,631.6 | 24,839.6 |
| Revenue | Median | | | | 5,820.2 | 11,564.2 | 23,628.2 | 24,873.8 |
| Revenue | Lowest | | | | 5,791.0 | 11,535.0 | 23,482.5 | 24,461.5 |
| Organic revenue growth (in %) | Number of Estimates | | | | 7 | 5 | 10 | 10 |
| Organic revenue growth (in %) | Highest | | | | 5.9 | 5.5 | 6.1 | 5.8 |
| Organic revenue growth (in %) | Consensus (Mean) | 5.0 | 6.0 | 7.0 | 5.6 | 5.0 | 5.5 | 5.2 |
| Organic revenue growth (in %) | Median | | | | 5.7 | 5.0 | 5.6 | 5.5 |
| Organic revenue growth (in %) | Lowest | | | | 4.6 | 4.4 | 4.8 | 4.1 |
| EBIT | Number of Estimates | | | | 7 | 7 | 12 | 12 |
| EBIT | Highest | | | | 696.1 | 1,374.1 | 2,794.9 | 3,014.0 |
| EBIT | Consensus (Mean) | 654.0 | 1,308.0 | 2,595.0 | 680.1 | 1,358.1 | 2,748.6 | 2,940.4 |
| EBIT | Median | | | | 685.4 | 1,363.4 | 2,749.2 | 2,950.0 |
| EBIT | Lowest | | | | 662.9 | 1,340.9 | 2,690.3 | 2,742.1 |
| EBIT margin (in %) | Number of Estimates | | | | 7 | 7 | 12 | 12 |
| EBIT margin (in %) | Highest | | | | 11.8 | 11.8 | 11.8 | 12.2 |
| EBIT margin (in %) | Consensus (Mean) | 11.7 | 11.7 | 11.5 | 11.7 | 11.7 | 11.6 | 11.8 |
| EBIT margin (in %) | Median | | | | 11.7 | 11.8 | 11.7 | 11.9 |
| EBIT margin (in %) | Lowest | | | | 11.4 | 11.6 | 11.3 | 11.1 |
| Net interest | Number of Estimates | | | | 6 | 6 | 11 | 11 |
| Net interest | Highest | | | | -75.0 | -143.0 | -311.5 | -282.0 |
| Net interest | Consensus (Mean) | -85.0 | -166.0 | -324.0 | -80.8 | -148.8 | -323.6 | -323.6 |
| Net interest | Median | | | | -81.3 | -149.3 | -323.4 | -315.0 |
| Net interest | Lowest | | | | -84.5 | -152.5 | -341.3 | -422.0 |
| Taxes | Number of Estimates | | | | 6 | 6 | 11 | 11 |
| Taxes | Highest | | | | -139.0 | -281.0 | -577.8 | -608.2 |
| Taxes | Consensus (Mean) | -143.0 | -286.0 | -582.0 | -148.5 | -290.5 | -600.9 | -654.6 |
| Taxes | Median | | | | -145.1 | -287.1 | -599.7 | -653.6 |
| Taxes | Lowest | | | | -168.2 | -310.2 | -637.6 | -709.6 |
| Tax rate in % | Number of Estimates | | | | 6 | 6 | 11 | 11 |
| Tax rate in % | Highest | | | | 27.3 | 25.3 | 26.2 | 26.7 |
| Tax rate in % | Consensus (Mean) | 25.1 | 25.0 | 25.6 | 24.8 | 24.0 | 24.8 | 25.0 |
| Tax rate in % | Median | | | | 24.5 | 23.9 | 24.5 | 25.0 |
| Tax rate in % | Lowest | | | | 23.1 | 23.2 | 24.2 | 24.3 |
| Core net income (from continuing operations) | Number of Estimates | | | | 6 | 6 | 10 | 10 |
| Core net income (from continuing operations) | Highest | | | | 462 | 931 | 1,861 | 2,028 |
| Core net income (from continuing operations) | Consensus (Mean) | 426 | 856 | 1,689 | 450 | 919 | 1,820 | 1,955 |
| Core net income (from continuing operations) | Median | | | | 447 | 916 | 1,819 | 1,957 |
| Core net income (from continuing operations) | Lowest | | | | 438 | 907 | 1,779 | 1,825 |
| Non-controlling interest in continuing operations | Number of Estimates | | | | 5 | 5 | 9 | 9 |
| Non-controlling interest in continuing operations | Highest | | | | -8.0 | -17.0 | -71.2 | -73.0 |
| Non-controlling interest in continuing operations | Consensus (Mean) | -14.0 | -28.0 | -70.0 | -19.0 | -28.0 | -75.8 | -81.2 |
| Non-controlling interest in continuing operations | Median | | | | -18.1 | -27.1 | -76.0 | -81.8 |
| Non-controlling interest in continuing operations | Lowest | | | | -28.3 | -37.3 | -84.4 | -91.6 |
| Core net income (from continuing operations; after minorities) | Number of Estimates | | | | 5 | 5 | 9 | 9 |
| Core net income (from continuing operations; after minorities) | Highest | | | | 439.7 | 899.7 | 1,785.1 | 1,950.1 |
| Core net income (from continuing operations; after minorities) | Consensus (Mean) | 412.0 | 828.0 | 1,619.0 | 431.0 | 891.0 | 1,748.8 | 1,880.6 |
| Core net income (from continuing operations; after minorities) | Median | | | | 429.1 | 889.1 | 1,745.1 | 1,873.8 |
| Core net income (from continuing operations; after minorities) | Lowest | | | | 426.9 | 886.9 | 1,709.4 | 1,751.8 |
| Core EPS (in EUR; from continuing operations; after minorities) | Number of Estimates | | | | 5 | 5 | 9 | 9 |
| Core EPS (in EUR; from continuing operations; after minorities) | Highest | | | | 0.86 | 1.68 | 3.17 | 3.46 |
| Core EPS (in EUR; from continuing operations; after minorities) | Consensus (Mean) | 0.73 | 1.47 | 2.87 | 0.78 | 1.60 | 3.10 | 3.33 |
| Core EPS (in EUR; from continuing operations; after minorities) | Median | | | | 0.76 | 1.58 | 3.09 | 3.33 |
| Core EPS (in EUR; from continuing operations; after minorities) | Lowest | | | | 0.75 | 1.57 | 3.04 | 3.11 |
| Result from investments (Equity method; FME: 32% of net income) | Number of Estimates | | | | 5 | 5 | 10 | 10 |
| Result from investments (Equity method; FME: 32% of net income) | Highest | | | | 72.5 | 170.5 | 343.6 | 352.1 |
| Result from investments (Equity method; FME: 32% of net income) | Consensus (Mean) | 80.0 | 154.0 | 376.0 | 63.9 | 161.9 | 273.0 | 305.4 |
| Result from investments (Equity method; FME: 32% of net income) | Median | | | | 71.5 | 169.5 | 277.0 | 320.8 |
| Result from investments (Equity method; FME: 32% of net income) | Lowest | | | | 49.7 | 147.7 | 219.0 | 232.0 |
| Net income attributable to FSE | Number of Estimates | | | | 5 | 5 | 10 | 10 |
| Net income attributable to FSE | Highest | | | | 512.2 | 1,070.2 | 2,128.7 | 2,275.2 |
| Net income attributable to FSE | Consensus (Mean) | 492.0 | 982.0 | 1,995.0 | 494.8 | 1,052.8 | 2,030.7 | 2,196.1 |
| Net income attributable to FSE | Median | | | | 498.4 | 1,056.4 | 2,026.5 | 2,197.9 |
| Net income attributable to FSE | Lowest | | | | 478.7 | 1,036.7 | 1,932.3 | 2,027.4 |
| EPS (in EUR) | Number of Estimates | | | | 5 | 5 | 10 | 10 |
| EPS (in EUR) | Highest | | | | 0.90 | 1.89 | 3.78 | 4.04 |
| EPS (in EUR) | Consensus (Mean) | 0.87 | 1.74 | 3.54 | 0.88 | 1.87 | 3.60 | 3.89 |
| EPS (in EUR) | Median | | | | 0.88 | 1.87 | 3.60 | 3.90 |
| EPS (in EUR) | Lowest | | | | 0.85 | 1.84 | 3.43 | 3.60 |
| Average number of ordinary shares (in million) | Number of Estimates | | | | 7 | 7 | 12 | 12 |
| Average number of ordinary shares (in million) | Highest | | | | 566.74 | 566.74 | 566.74 | 567.74 |
| Average number of ordinary shares (in million) | Consensus (Mean) | 563.24 | 563.24 | 563.24 | 563.81 | 563.77 | 563.74 | 563.82 |
| Average number of ordinary shares (in million) | Median | | | | 563.24 | 563.24 | 563.24 | 563.24 |
| Average number of ordinary shares (in million) | Lowest | | | | 561.24 | 562.24 | 563.24 | 563.24 |
| Fresenius Kabi, revenue | Number of Estimates | | | | 7 | 7 | 10 | 10 |
| Fresenius Kabi, revenue | Highest | | | | 2,229.3 | 4,379.3 | 9,141.1 | 9,746.4 |
| Fresenius Kabi, revenue | Consensus (Mean) | 2,111.0 | 4,257.0 | 8,612.0 | 2,188.3 | 4,338.3 | 8,980.8 | 9,547.8 |
| Fresenius Kabi, revenue | Median | | | | 2,179.0 | 4,329.0 | 8,977.7 | 9,561.3 |
| Fresenius Kabi, revenue | Lowest | | | | 2,153.1 | 4,303.1 | 8,849.8 | 9,277.2 |
| Fresenius Kabi, organic revenue growth (in %) | Number of Estimates | | | | 7 | 5 | 9 | 9 |
| Fresenius Kabi, organic revenue growth (in %) | Highest | | | | 7.5 | 6.8 | 8.1 | 7.6 |
| Fresenius Kabi, organic revenue growth (in %) | Consensus (Mean) | 6.0 | 5.0 | 7.0 | 6.5 | 6.3 | 6.7 | 6.3 |
| Fresenius Kabi, organic revenue growth (in %) | Median | | | | 6.9 | 6.6 | 6.8 | 6.3 |
| Fresenius Kabi, organic revenue growth (in %) | Lowest | | | | 4.6 | 5.3 | 5.3 | 4.8 |
| thereof Medtech, revenue | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| thereof Medtech, revenue | Highest | | | | 416.5 | 808.5 | 1,689.9 | 1,827.0 |
| thereof Medtech, revenue | Consensus (Mean) | 392.0 | 791.0 | 1,610.0 | 405.3 | 797.3 | 1,665.0 | 1,777.1 |
| thereof Medtech, revenue | Median | | | | 403.8 | 795.8 | 1,673.4 | 1,777.7 |
| thereof Medtech, revenue | Lowest | | | | 395.9 | 787.9 | 1,626.1 | 1,724.3 |
| thereof Nutrition, revenue | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| thereof Nutrition, revenue | Highest | | | | 609.6 | 1,219.6 | 2,515.8 | 2,691.9 |
| thereof Nutrition, revenue | Consensus (Mean) | 581.0 | 1,193.0 | 2,396.0 | 600.8 | 1,210.8 | 2,486.2 | 2,647.1 |
| thereof Nutrition, revenue | Median | | | | 599.0 | 1,209.0 | 2,490.9 | 2,640.6 |
| thereof Nutrition, revenue | Lowest | | | | 586.8 | 1,196.8 | 2,467.9 | 2,616.0 |
| thereof Biopharma, revenue | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| thereof Biopharma, revenue | Highest | | | | 251.9 | 489.9 | 1,158.4 | 1,436.5 |
| thereof Biopharma, revenue | Consensus (Mean) | 190.0 | 380.0 | 871.0 | 245.6 | 483.6 | 1,076.6 | 1,269.8 |
| thereof Biopharma, revenue | Median | | | | 247.0 | 485.0 | 1,065.8 | 1,279.5 |
| thereof Biopharma, revenue | Lowest | | | | 236.1 | 474.1 | 1,017.7 | 1,120.1 |
| Subtotal Growth Vectors, revenue | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| Subtotal Growth Vectors, revenue | Highest | | | | 1,272.8 | 2,512.8 | 5,313.8 | 5,865.3 |
| Subtotal Growth Vectors, revenue | Consensus (Mean) | 1,164.0 | 2,365.0 | 4,877.0 | 1,251.8 | 2,491.8 | 5,227.9 | 5,694.0 |
| Subtotal Growth Vectors, revenue | Median | | | | 1,249.0 | 2,489.0 | 5,239.7 | 5,714.3 |
| Subtotal Growth Vectors, revenue | Lowest | | | | 1,224.0 | 2,464.0 | 5,133.5 | 5,486.5 |
| Pharma (IV Drugs & Fluids), revenue | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| Pharma (IV Drugs & Fluids), revenue | Highest | | | | 968.2 | 1,879.2 | 3,788.1 | 3,905.9 |
| Pharma (IV Drugs & Fluids), revenue | Consensus (Mean) | 947.0 | 1,893.0 | 3,735.0 | 936.3 | 1,847.3 | 3,735.9 | 3,836.2 |
| Pharma (IV Drugs & Fluids), revenue | Median | | | | 929.0 | 1,840.0 | 3,742.2 | 3,832.0 |
| Pharma (IV Drugs & Fluids), revenue | Lowest | | | | 918.6 | 1,829.6 | 3,660.3 | 3,770.1 |
| Fresenius Kabi, EBIT | Number of Estimates | | | | 7 | 7 | 10 | 10 |
| Fresenius Kabi, EBIT | Highest | | | | 362.8 | 720.8 | 1,526.1 | 1,704.0 |
| Fresenius Kabi, EBIT | Consensus (Mean) | 346.0 | 706.0 | 1,413.0 | 355.0 | 713.0 | 1,495.3 | 1,638.2 |
| Fresenius Kabi, EBIT | Median | | | | 354.8 | 712.8 | 1,495.2 | 1,643.6 |
| Fresenius Kabi, EBIT | Lowest | | | | 347.6 | 705.6 | 1,458.1 | 1,534.9 |
| Fresenius Kabi, EBIT margin | Number of Estimates | | | | 7 | 7 | 10 | 10 |
| Fresenius Kabi, EBIT margin | Highest | | | | 16.7 | 16.7 | 16.9 | 18.0 |
| Fresenius Kabi, EBIT margin | Consensus (Mean) | 16.4 | 16.6 | 16.4 | 16.2 | 16.4 | 16.6 | 17.2 |
| Fresenius Kabi, EBIT margin | Median | | | | 16.1 | 16.4 | 16.7 | 17.1 |
| Fresenius Kabi, EBIT margin | Lowest | | | | 15.8 | 16.2 | 16.5 | 16.5 |
| thereof Growth Vectors, EBIT | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| thereof Growth Vectors, EBIT | Highest | | | | 215.1 | 410.1 | 913.8 | 1,051.9 |
| thereof Growth Vectors, EBIT | Consensus (Mean) | 166.0 | 350.0 | 743.0 | 197.6 | 392.6 | 850.2 | 958.5 |
| thereof Growth Vectors, EBIT | Median | | | | 199.2 | 394.2 | 845.2 | 969.9 |
| thereof Growth Vectors, EBIT | Lowest | | | | 173.8 | 368.8 | 806.8 | 847.5 |
| thereof Growth Vectors, EBIT margin (in %) | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| thereof Growth Vectors, EBIT margin (in %) | Highest | | | | 17.0 | 16.4 | 17.5 | 18.6 |
| thereof Growth Vectors, EBIT margin (in %) | Consensus (Mean) | 14.3 | 14.8 | 15.2 | 15.8 | 15.8 | 16.3 | 16.8 |
| thereof Growth Vectors, EBIT margin (in %) | Median | | | | 15.8 | 15.8 | 16.0 | 16.6 |
| thereof Growth Vectors, EBIT margin (in %) | Lowest | | | | 14.2 | 15.0 | 15.6 | 15.4 |
| thereof Pharma (IV Drugs & Fluids), EBIT | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| thereof Pharma (IV Drugs & Fluids), EBIT | Highest | | | | 205.7 | 399.7 | 823.3 | 931.5 |
| thereof Pharma (IV Drugs & Fluids), EBIT | Consensus (Mean) | 206.0 | 422.0 | 813.0 | 197.2 | 391.2 | 797.5 | 828.7 |
| thereof Pharma (IV Drugs & Fluids), EBIT | Median | | | | 199.7 | 393.7 | 798.0 | 817.9 |
| thereof Pharma (IV Drugs & Fluids), EBIT | Lowest | | | | 188.3 | 382.3 | 761.8 | 777.1 |
| thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Highest | | | | 21.8 | 21.5 | 22.0 | 24.2 |
| thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Consensus (Mean) | 21.8 | 22.3 | 21.8 | 21.1 | 21.2 | 21.3 | 21.6 |
| thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Median | | | | 21.3 | 21.3 | 21.4 | 21.3 |
| thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Lowest | | | | 20.2 | 20.7 | 20.5 | 20.5 |
| thereof Corporate, EBIT | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| thereof Corporate, EBIT | Highest | | | | -26.0 | -57.0 | -120.0 | -100.0 |
| thereof Corporate, EBIT | Consensus (Mean) | -27.0 | -67.0 | -143.0 | -39.8 | -70.8 | -158.3 | -160.3 |
| thereof Corporate, EBIT | Median | | | | -37.6 | -68.6 | -148.2 | -151.9 |
| thereof Corporate, EBIT | Lowest | | | | -60.0 | -91.0 | -220.0 | -231.8 |
| Fresenius Helios, revenue | Number of Estimates | | | | 7 | 7 | 10 | 10 |
| Fresenius Helios, revenue | Highest | | | | 3,552.2 | 7,053.2 | 14,254.6 | 14,996.0 |
| Fresenius Helios, revenue | Consensus (Mean) | 3,370.0 | 6,764.0 | 13,550.0 | 3,539.3 | 7,040.3 | 14,202.0 | 14,850.2 |
| Fresenius Helios, revenue | Median | | | | 3,538.5 | 7,039.5 | 14,199.6 | 14,863.3 |
| Fresenius Helios, revenue | Lowest | | | | 3,528.5 | 7,029.5 | 14,144.6 | 14,682.8 |
| Fresenius Helios, organic revenue growth (in %) | Number of Estimates | | | | 7 | 5 | 9 | 9 |
| Fresenius Helios, organic revenue growth (in %) | Highest | | | | 5.5 | 4.5 | 5.2 | 5.3 |
| Fresenius Helios, organic revenue growth (in %) | Consensus (Mean) | 5.0 | 6.0 | 7.0 | 5.1 | 4.3 | 4.8 | 4.5 |
| Fresenius Helios, organic revenue growth (in %) | Median | | | | 5.2 | 4.3 | 4.9 | 4.6 |
| Fresenius Helios, organic revenue growth (in %) | Lowest | | | | 4.7 | 4.0 | 4.4 | 3.5 |
| Helios Germany, revenue | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| Helios Germany, revenue | Highest | | | | 2,101.1 | 4,193.1 | 8,527.1 | 8,953.4 |
| Helios Germany, revenue | Consensus (Mean) | 2,001.0 | 4,047.0 | 8,121.0 | 2,088.2 | 4,180.2 | 8,468.8 | 8,808.6 |
| Helios Germany, revenue | Median | | | | 2,081.0 | 4,173.0 | 8,470.6 | 8,786.1 |
| Helios Germany, revenue | Lowest | | | | 2,081.0 | 4,173.0 | 8,410.0 | 8,704.1 |
| Helios Spain, revenue | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| Helios Spain, revenue | Highest | | | | 1,465.0 | 2,874.0 | 5,754.7 | 6,153.8 |
| Helios Spain, revenue | Consensus (Mean) | 1,369.0 | 2,717.0 | 5,429.0 | 1,451.2 | 2,860.2 | 5,729.2 | 6,046.5 |
| Helios Spain, revenue | Median | | | | 1,451.1 | 2,860.1 | 5,730.9 | 6,042.5 |
| Helios Spain, revenue | Lowest | | | | 1,437.5 | 2,846.5 | 5,694.1 | 5,978.8 |
| Fresenius Helios, EBIT | Number of Estimates | | | | 7 | 7 | 10 | 10 |
| Fresenius Helios, EBIT | Highest | | | | 382.0 | 750.0 | 1,488.0 | 1,588.2 |
| Fresenius Helios, EBIT | Consensus (Mean) | 337.0 | 670.0 | 1,328.0 | 374.2 | 742.2 | 1,457.7 | 1,516.4 |
| Fresenius Helios, EBIT | Median | | | | 377.1 | 745.1 | 1,458.6 | 1,505.3 |
| Fresenius Helios, EBIT | Lowest | | | | 353.4 | 721.4 | 1,432.2 | 1,454.8 |
| Fresenius Helios, EBIT margin (in %) | Number of Estimates | | | | 7 | 7 | 10 | 10 |
| Fresenius Helios, EBIT margin (in %) | Highest | | | | 10.8 | 10.6 | 10.4 | 10.7 |
| Fresenius Helios, EBIT margin (in %) | Consensus (Mean) | 10.0 | 9.9 | 9.8 | 10.6 | 10.5 | 10.3 | 10.2 |
| Fresenius Helios, EBIT margin (in %) | Median | | | | 10.7 | 10.6 | 10.3 | 10.1 |
| Fresenius Helios, EBIT margin (in %) | Lowest | | | | 9.9 | 10.2 | 10.1 | 9.9 |
| Helios Germany, EBIT | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| Helios Germany, EBIT | Highest | | | | 178.6 | 351.6 | 755.3 | 776.0 |
| Helios Germany, EBIT | Consensus (Mean) | 150.0 | 307.0 | 662.0 | 174.5 | 347.5 | 733.1 | 738.1 |
| Helios Germany, EBIT | Median | | | | 176.9 | 349.9 | 736.2 | 741.0 |
| Helios Germany, EBIT | Lowest | | | | 163.9 | 336.9 | 715.6 | 699.3 |
| Helios Spain, EBIT | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| Helios Spain, EBIT | Highest | | | | 205.1 | 400.1 | 737.1 | 817.4 |
| Helios Spain, EBIT | Consensus (Mean) | 189.0 | 365.0 | 669.0 | 200.3 | 395.3 | 722.7 | 769.5 |
| Helios Spain, EBIT | Median | | | | 200.3 | 395.3 | 723.1 | 763.5 |
| Helios Spain, EBIT | Lowest | | | | 191.6 | 386.6 | 709.0 | 741.5 |
| Helios Corporate, EBIT | Number of Estimates | | | | 7 | 7 | 8 | 8 |
| Helios Corporate, EBIT | Highest | | | | 0.0 | 0.0 | 0.0 | 0.0 |
| Helios Corporate, EBIT | Consensus (Mean) | -2.0 | -2.0 | -3.0 | -0.6 | -0.6 | -1.8 | -1.8 |
| Helios Corporate, EBIT | Median | | | | -0.3 | -0.3 | -1.5 | -1.5 |
| Helios Corporate, EBIT | Lowest | | | | -2.1 | -2.1 | -5.0 | -5.2 |
| Corporate/Other, revenue | Number of Estimates | | | | 7 | 7 | 10 | 10 |
| Corporate/Other, revenue | Highest | | | | 101.9 | 193.9 | 732.3 | 754.3 |
| Corporate/Other, revenue | Consensus (Mean) | 90.0 | 181.0 | 392.0 | 94.8 | 186.8 | 436.7 | 450.6 |
| Corporate/Other, revenue | Median | | | | 92.7 | 184.7 | 404.2 | 422.0 |
| Corporate/Other, revenue | Lowest | | | | 85.5 | 177.5 | 392.0 | 392.0 |
| Corporate/Other, EBIT | Number of Estimates | | | | 7 | 7 | 10 | 10 |
| Corporate/Other, EBIT | Highest | | | | -38.0 | -86.0 | -192.1 | -197.1 |
| Corporate/Other, EBIT | Consensus (Mean) | -29.0 | -68.0 | -146.0 | -49.1 | -97.1 | -208.4 | -221.1 |
| Corporate/Other, EBIT | Median | | | | -50.0 | -98.0 | -200.0 | -216.8 |
| Corporate/Other, EBIT | Lowest | | | | -60.0 | -108.0 | -250.0 | -260.0 |